{"id":13997,"date":"2018-11-08T09:43:50","date_gmt":"2018-11-08T09:43:50","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/"},"modified":"2026-02-11T09:46:59","modified_gmt":"2026-02-11T09:46:59","slug":"sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics","status":"publish","type":"post","link":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/","title":{"rendered":"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics."},"content":{"rendered":"<p><a href=\"http:\/\/www.sitryx.com\/\">Sitryx Therapeutics<\/a> choisit Sygnature Discovery pour une collaboration int\u00e9gr\u00e9e en mati\u00e8re de d\u00e9couverte de m\u00e9dicaments multi-cibles.<\/p>\n<p>Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que le statut \u00e9nerg\u00e9tique des cellules joue un r\u00f4le crucial dans la r\u00e9gulation du comportement des cellules impliqu\u00e9es dans les maladies en immuno-oncologie et en immuno-inflammation. La correction de la fonction des cellules immunitaires et\/ou l&rsquo;inhibition de la croissance des cellules tumorales par le ciblage des voies m\u00e9taboliques pourraient ouvrir la voie \u00e0 de nouvelles approches compl\u00e9mentaires et hautement diff\u00e9renci\u00e9es pour traiter un large \u00e9ventail de maladies graves. <\/p>\n<p>La science exclusive de Sitryx est dirig\u00e9e par une \u00e9quipe de direction tr\u00e8s exp\u00e9riment\u00e9e, soutenue par l&rsquo;exp\u00e9rience de <a href=\"https:\/\/www.gsk.com\/\">GlaxoSmithKline<\/a> en mati\u00e8re de d\u00e9couverte de m\u00e9dicaments et par des fondateurs universitaires de renomm\u00e9e mondiale, en plus de l&rsquo;expertise significative de Sygnature dans la d\u00e9couverte de m\u00e9dicaments en immuno-oncologie et en immunologie. Sitryx Therapeutics a \u00e9t\u00e9 fond\u00e9e par six chercheurs de renomm\u00e9e mondiale dans le domaine de l&rsquo;immunologie et de l&rsquo;immunor\u00e9gulation, dont Houman Ashrafian, Luke O&rsquo;Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum et Paul Peter Tak.<\/p>\n<p>Commentant cette collaboration, le PDG et fondateur de Sygnature, <a href=\"https:\/\/www.sygnaturediscovery.com\/team-members\/dr-simon-hirst\/\">le Dr Simon Hirst,<\/a> a d\u00e9clar\u00e9&nbsp;: \u00ab&nbsp;Nous sommes ravis d\u2019avoir \u00e9t\u00e9 choisis par Sitryx pour soutenir leurs travaux de recherche novateurs visant \u00e0 d\u00e9velopper des th\u00e9rapies modifiant l\u2019\u00e9volution de la maladie sur de multiples cibles biologiques en immuno-oncologie et en immuno-inflammation. Notre expertise approfondie en immuno-oncologie et en immunologie nous permettra d\u2019explorer efficacement ces domaines complexes de la biologie afin de faciliter l\u2019identification et l\u2019optimisation de nouvelles petites mol\u00e9cules s\u00e9lectives, tout en d\u00e9veloppant une compr\u00e9hension fine de leur mode d\u2019action.&nbsp;\u00bb<\/p>\n<p>Le Dr Neil Weir, PDG de Sitryx, a d\u00e9clar\u00e9&nbsp;: \u00ab&nbsp;Sygnature Discovery jouit d\u2019une solide r\u00e9putation en tant que fournisseur de services int\u00e9gr\u00e9s de pointe en mati\u00e8re de d\u00e9couverte de m\u00e9dicaments et de services pr\u00e9cliniques. L\u2019\u00e9quipe de Sitryx poss\u00e8de une vaste exp\u00e9rience et un succ\u00e8s reconnu dans la d\u00e9couverte et le d\u00e9veloppement de nouveaux m\u00e9dicaments. Nous mettrons en commun notre savoir-faire et notre expertise consid\u00e9rables afin de proposer de nouvelles th\u00e9rapies hautement efficaces modifiant l\u2019\u00e9volution de la maladie en immuno-oncologie et en immuno-inflammation.&nbsp;\u00bb <\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":13998,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"category":[973,819,817,900,823,1119],"tags":[825,1377],"class_list":["post-13997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-classes-cibles","category-decouverte-integree-de-medicaments","category-domaines-therapeutiques","category-ii","category-oncologie","category-petites-molecules","tag-decouverte-de-medicaments","tag-sitryx-therapeutique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics. - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics. - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-08T09:43:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T09:46:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/T-cells-attacking-cancer-cell.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"1050\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"pnpd-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"pnpd-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/\"},\"author\":{\"name\":\"pnpd-admin\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\"},\"headline\":\"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics.\",\"datePublished\":\"2018-11-08T09:43:50+00:00\",\"dateModified\":\"2026-02-11T09:46:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/\"},\"wordCount\":430,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/T-cells-attacking-cancer-cell.jpg\",\"keywords\":[\"D\u00e9couverte de m\u00e9dicaments\",\"Sitryx Th\u00e9rapeutique\"],\"articleSection\":[\"Classes cibles\",\"D\u00e9couverte int\u00e9gr\u00e9e de m\u00e9dicaments\",\"Domaines th\u00e9rapeutiques\",\"I&amp;I\",\"oncologie\",\"petites mol\u00e9cules\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/\",\"name\":\"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics. - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/T-cells-attacking-cancer-cell.jpg\",\"datePublished\":\"2018-11-08T09:43:50+00:00\",\"dateModified\":\"2026-02-11T09:46:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/T-cells-attacking-cancer-cell.jpg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/T-cells-attacking-cancer-cell.jpg\",\"width\":1500,\"height\":1050},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\",\"name\":\"pnpd-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"caption\":\"pnpd-admin\"},\"sameAs\":[\"http:\\\/\\\/www.sygnaturediscovery.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics. - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/","og_locale":"fr_CA","og_type":"article","og_title":"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics. - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/","og_site_name":"Sygnature","article_published_time":"2018-11-08T09:43:50+00:00","article_modified_time":"2026-02-11T09:46:59+00:00","og_image":[{"width":1500,"height":1050,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/T-cells-attacking-cancer-cell.jpg","type":"image\/jpeg"}],"author":"pnpd-admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"pnpd-admin","Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/"},"author":{"name":"pnpd-admin","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448"},"headline":"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics.","datePublished":"2018-11-08T09:43:50+00:00","dateModified":"2026-02-11T09:46:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/"},"wordCount":430,"publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/T-cells-attacking-cancer-cell.jpg","keywords":["D\u00e9couverte de m\u00e9dicaments","Sitryx Th\u00e9rapeutique"],"articleSection":["Classes cibles","D\u00e9couverte int\u00e9gr\u00e9e de m\u00e9dicaments","Domaines th\u00e9rapeutiques","I&amp;I","oncologie","petites mol\u00e9cules"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/","name":"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics. - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/T-cells-attacking-cancer-cell.jpg","datePublished":"2018-11-08T09:43:50+00:00","dateModified":"2026-02-11T09:46:59+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/T-cells-attacking-cancer-cell.jpg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/T-cells-attacking-cancer-cell.jpg","width":1500,"height":1050},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-discovery-specialiste-de-la-decouverte-de-medicaments-multi-cibles-collabore-avec-sitryx-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Sygnature Discovery, sp\u00e9cialiste de la d\u00e9couverte de m\u00e9dicaments multi-cibles, collabore avec Sitryx Therapeutics."}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448","name":"pnpd-admin","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","caption":"pnpd-admin"},"sameAs":["http:\/\/www.sygnaturediscovery.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/comments?post=13997"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13997\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/13998"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=13997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=13997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/tags?post=13997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}